Please assess the completion status of the following clinical trial:

Trial Title: Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria Disease Related~1. High risk SMM, defined as follows by Mayo Clinic criteria:~   1. Bone marrow plasma cells between 10% and 60%~  2. Serum M-protein ≥ 3 g/dL \[except IgA ≥ 2 g/dL\] or urine M-protein \> 500 mg per 24 hours~  3. Serum free light chain ratio \< 0.126 or \> 8; an involved to uninvolved ratio of ≥ 100 is permitted~  4. Measurable disease, defined as: M-protein ≥ 1 g/dL OR Bence-Jones protein (BJP) \> 200 mg/24 hr OR involved free light chain \> 100 mg/dL~2. Diagnosed with SMM within the last 4 years~Laboratory~1. Adequate hematologic function independent of transfusion and growth factor support for at least 7 days prior to screening, with the exception of pegylated G-CSF (pegfilgrastim) and darbopoetin which require at least 14 days prior to screening defined as:~   * Absolute neutrophil count \> 750 cells/mm3 (1.0 x 109/L).~  * Platelet count \> 75,000 cells/mm3 (75 x 109/L).~2. Adequate hepatic and renal function defined as:~   * Serum aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x upper limit of normal (ULN).~  * Estimated creatinine clearance ≥ 30 ml/min (Cockcroft-Gault)~  * Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin, in which case the total bilirubin should be \< 3 x ULN)~3. PT/INR \< 1.5 x ULN and PTT (aPTT) \< 1.5 x ULN~   Demographic~4. Men and women ≥ 18 years of age~5. Eastern Cooperative Oncology Group (ECOG) performance status of \< 2~Exclusion Criteria Disease-Related~1. No end organ damage attributable to a plasma cell disorder, defined as having ANY of the following:~   1. Hypercalcemia: Serum calcium \> 1 mg/dL above the upper limit of normal or \> 11 mg/dL~  2. Renal insufficiency: Serum creatinine \> 2 mg/dL or creatinine clearance \< 30 mL per min~  3. Anemia: Hemoglobin value \> 2 g/dL below the upper limit of normal or a hemoglobin value \< 10 g/dL~  4. Bone lesions: One or more lytic lesions on skeletal radiography, CT, MRI, PET-CT, or PET-MRI~2. Bone marrow plasma cells \< 10% or \> 60%~3. Has received prior anti-myeloma therapy of any type~4. Has received prior bisphosphonate therapy~5. Has received an investigational drug, investigational vaccine, or has used an investigational medical device within 4 weeks or 4 half-lives, whichever is longer, before Cycle 1, Day 1 of study therapy~6. Osteoporosis, defined as having a T-score on DEXA of ≤ -2.5~Concurrent Conditions~1. History of other malignancies, except:~   * Malignancy treated with curative intent and with no known active disease present for ≥ 3 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician~  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease~  * Adequately treated carcinoma in situ without evidence of disease~2. Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc). Any use of corticosteroids EITHER for \> 14 days OR at dosages \> 20 mg/day of prednisone or equivalent is prohibited.~3. Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug~4. Recent infection requiring systemic treatment that was completed ≤ 14 days before the first dose of study drug~5. Known bleeding disorders (eg, von Willebrand's disease) or hemophilia~6. History of stroke or intracranial hemorrhage within 6 months prior to enrollment~7. Known HIV, HCV or HBV infection. Subjects who are positive for hepatitis B core antibody or hepatitis B surface antigen must have a negative polymerase chain reaction (PCR) result before enrollment. Those who are PCR positive will be excluded.~8. Any uncontrolled active systemic infection~9. Major surgery within 4 weeks of first dose of study drug~10. Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigators' opinion, could compromise the subject's safety or put the study outcomes at undue risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ibrutinib (Type: EXPERIMENTAL): Ibrutinib (trademark name is IMBRUVICA®). 560 mg dose administered on a continuous basis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues